Lipella Pharmaceuticals Inc. has voluntarily entered a bankruptcy process in response to challenging financial circumstances. The biotechnology firm, based in Pittsburgh, was delisted from the Nasdaq Capital Market in June 2025.
In a recent announcement, the company indicated its intention to pursue the sale of its assets while continuing operations under court supervision throughout the Chapter 11 proceedings.
Chapter 11 Filing Details
The company submitted its voluntary petition on March 30, 2026, as reported in a press release by GlobeNewswire. The case is being managed in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
Company Seeks to Sell Assets
Lipella Pharmaceuticals Inc. has provided information regarding its asset sale plan as part of the bankruptcy filing. The company aims to utilize a Section 363 sale process designed to maximise value for its creditors.
PacerMonitor has stated that the case, filed under number 2:26-bk-20879, is currently active, with Judge Carlota M. Bohm overseeing the proceedings.
Bankruptcy Follows Nasdaq Delisting
On June 20, 2025, the company disclosed that the Nasdaq Hearings Panel had decided to delist its common stock from the Nasdaq Capital Market. This delisting occurred after Nasdaq determined that several private placement transactions carried out by the biotechnology company between December 2024 and March 2025 did not comply with its regulations. These included violations of Listing Rules 5100 (Public Interest Concern), 5640 (Voting Rights), and 5635 (Shareholder Approval).
Furthermore, the delisting was prompted by the company’s issuance of Series C voting convertible shares and warrants to advisors in a manner inconsistent with Nasdaq’s rules.
Despite the delisting, Lipella Pharmaceuticals Inc. has expressed its commitment to advancing its drug development programmes, including LP-10 for haemorrhagic cystitis and LP-310 for oral lichen planus.
Ongoing Operations Amid Bankruptcy
The company has stated that it is seeking customary first-day motions to maintain regular operations under court supervision. These motions pertain to the management of cash systems and the payment of employee wages and benefits.
The Chapter 11 filing signifies a critical juncture for Lipella Pharmaceuticals Inc. as it endeavours to reorganise its finances and uphold value through asset sales. The outcome of this process is anticipated to be crucial for the company’s future and the potential recovery for its creditors.